Thomas G. Wiggans - 10 Jun 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Reporting relationship: Director
Issuer ticker: PCRX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 21:07:30 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristen Williams, Attorney-in-Fact

Key filing fact

Thomas G. Wiggans filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 12 Jun 2026.

Key facts

This page summarizes Thomas G. Wiggans's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 21:07.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001208907 Primary reporting owner

WIGGANS THOMAS G

Relationship: Director
Address: C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE
Signature: /s/ Kristen Williams, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +32,675
Change %
Price: $0.000000^*
Shares after: 32,675
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,675
Exercise price: $23.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.